All In Biotech

Drug Trial Radar · NCT07176390

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 185 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

185

Actual

Start

Oct 8, 2025

Primary completion

Sep 7, 2026

Study completion Mar 1, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Conditions

  • Arthritis, Rheumatoid

Interventions

  • TulisokibartDrug

    Subcutaneous (SC) administration

  • PlaceboDrug

    SC Injection

  • MethotrexateDrug

    Background Therapy - SC injection or oral administration. Per protocol, parenteral administration is allowed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving American College of Rheumatology 20% Response Criteria (ACR20) at Week 12Time frame: Week 12

Locations

61 sites in 11 countries. Site status is shown where the registry gives one.

  • Arizona Arthritis & Rheumatology Associates, P.C. ( Site 1018)

    Glendale, Arizona

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa ( Site 1033)

    Mesa, Arizona

  • Arthritis & Osteoporosis Medical Center - La Palma ( Site 1024)

    La Palma, California

  • Tekton Research, LLC. ( Site 1008)

    Fort Collins, Colorado

  • Sweet Hope Research Specialty, Inc ( Site 1015)

    Hialeah, Florida

  • HMD Research LLC ( Site 1016)

    Orlando, Florida

  • Greater Chicago Specialty Physicians - Orland Park ( Site 1043)

    Orland Park, Illinois

  • AA Medical Research Center ( Site 1027)

    Grand Blanc, Michigan

  • Kansas City Physician Partners ( Site 1032)

    Kansas City, Missouri

  • Physician Research Collaboration, LLC ( Site 1002)

    Lincoln, Nebraska

  • altoona center for clinical research ( Site 1005)

    Duncansville, Pennsylvania

  • Rheumatology Specialty Center ( Site 1030)

    Willow Grove, Pennsylvania

  • AARA Clinical Research - Murfreesboro Medical Clinic ( Site 1034)

    Murfreesboro, Tennessee

  • Rheumatology Associates ( Site 1026)

    Arlington, Texas

  • Epic Medical Research ( Site 1004)

    Red Oak, Texas

  • Advanced Rheumatology of Houston - Woodlands ( Site 1000)

    The Woodlands, Texas

  • CIUSSS de l'Estrie - CHUS, Hotel-Dieu de Sherbrooke ( Site 1106)

    Sherbrooke, Quebec, Canada

  • Centre de Recherche Musculo-Squelettique ( Site 1101)

    Trois-Rivières, Quebec, Canada

  • Centro de Estudios GyC ( Site 1206)

    Santiago, Region M. de Santiago, Chile

  • Clinica Dermacross ( Site 1203)

    Santiago, Region M. de Santiago, Chile

  • CECIM ( Site 1208)

    Santiago, Region M. de Santiago, Chile

  • Pontificia Universidad Catolica de Chile-CICUC ( Site 1209)

    Santiago, Region M. de Santiago, Chile

  • Peking University First Hospital ( Site 2511)

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Xiamen University. ( Site 2510)

    Xiamen, Fujian, China

  • The Third Affiliated Hospital, Sun Yat-sen University ( Site 2514)

    Guangzhou, Guangdong, China

  • Xinxiang Central Hospital ( Site 2501)

    Xinxiang, Henan, China

  • Pingxiang People's Hospital ( Site 2512)

    Pingxiang, Jiangxi, China

  • Linfen Central Hospital ( Site 2507)

    Linfen, Shanxi, China

  • PEOPLE'S HOSPITAL OF XINJIANG UYGUR AUTONOMOUS REGION ( Site 2515)

    Ürümqi, Xinjiang, China

  • Taizhou Hospital of Zhejiang Province ( Site 2506)

    Linhai, Zhejiang, China

  • Clinica de la Costa S.A.S. ( Site 1301)

    Barranquilla, Atlántico, Colombia

  • CIREEM SAS ( Site 1304)

    Bogota, Cundinamarca, Colombia

  • Fundación Valle del Lili ( Site 1305)

    Cali, Valle del Cauca Department, Colombia

  • Rheumatologische Schwerpunktpraxis ( Site 1603)

    Berlin, Germany

  • HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg G ( Site 1602)

    Hamburg, Germany

  • Medicover München Ost MVZ ( Site 1607)

    München, Bavaria, Germany

  • Rheuma-Research Lausitz ( Site 1604)

    Cottbus, Brandenburg, Germany

  • Rheumazentrum Ratingen Studienambulanz ( Site 1601)

    Ratingen, North Rhine-Westphalia, Germany

  • Kai Clinic ( Site 2600)

    Miyazaki, Japan

  • Toshin Yoshida Internal Medicine Rheumatology ( Site 2606)

    Hanishina-gun, Nagano, Japan

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.